bullish
Alfresa Holdings (2784 JP): Looking Ahead Through 2022–25 Mid-Term Management Plan
369 Views25 Jun 2022 19:02
SUMMARY
- Alfresa Holdings (2784 JP) reported revenue decline in FY21. Apart from market wide negative impact of COVID-19 and drug price revision, suspended qualification for public bidding tenders affected the company.
- In FY22, the company is expected to be back to its growth path with less impact of bidding suspension and increasing focus on high growth areas.
- According to its 2022–2024 mid-term management plan, Alfresa targets to achieve a revenue of ¥2.7 trillion and operating income margin of 1.5% or higher by FY25.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- JAPAN BUYBACKS - Alfresa (2784) Cheap Stock, Uncheapening, Goes Big15 May 2023
- Alfresa Holdings (2784 JP): FY23 Result Is Expected to Exceed Previous Forecast08 May 2023
- Alfresa Holdings (2784 JP): H1FY23 Review- Better-Than-Expected Performance; Outlook Is Positive20 Nov 2022
- Alfresa Holdings (2784 JP): Looking Ahead Through 2022–25 Mid-Term Management Plan25 Jun 2022
x